SLC1A2 and Alzheimer disease: Prolonged administration of CEF in aged 3xTg-AD mice showed a substantial upregulation GLT-1 expression, improving cognitive impairments, preserving synaptic proteins and reducing of tau pathology. But both beta amyloid (Aβ) and amyloid precursor protein were not significantly altered in CEF treated group compared to control group.